← Back to Screener
Schrodinger, Inc. Common Stock (SDGR)
Price$12.80
Favorite Metrics
Price vs S&P 500 (26W)-44.07%
Price vs S&P 500 (4W)-6.83%
Market Capitalization$911.00M
All Metrics
P/CF (Annual)65.54x
Book Value / Share (Quarterly)$4.94
P/TBV (Annual)4.70x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)12.23%
Cash Flow / Share (Quarterly)$0.17
Price vs S&P 500 (YTD)-35.12%
Gross Margin (TTM)55.74%
Net Profit Margin (TTM)-40.36%
EPS (TTM)$-1.41
10-Day Avg Trading Volume1.59M
EPS Excl Extra (TTM)$-1.41
Revenue Growth (5Y)18.81%
EPS (Annual)$-1.41
ROI (Annual)-28.37%
Gross Margin (Annual)55.74%
Net Profit Margin (5Y Avg)-53.39%
Cash / Share (Quarterly)$5.37
Revenue Growth QoQ (YoY)-1.23%
ROA (Last FY)-14.22%
Revenue Growth TTM (YoY)23.29%
EBITD / Share (TTM)$-2.19
ROE (5Y Avg)-23.34%
Operating Margin (TTM)-65.23%
Cash Flow / Share (Annual)$0.17
P/B Ratio2.50x
P/B Ratio (Quarterly)3.62x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.66x
Net Interest Coverage (TTM)-63.83x
ROA (TTM)-14.69%
EPS Incl Extra (Annual)$-1.41
Current Ratio (Annual)2.75x
Quick Ratio (Quarterly)2.68x
3-Month Avg Trading Volume1.27M
52-Week Price Return-51.05%
EV / Free Cash Flow (Annual)54.63x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.60
P/S Ratio (Annual)3.56x
Asset Turnover (Annual)0.35x
52-Week High$27.63
Operating Margin (5Y Avg)-81.97%
EPS Excl Extra (Annual)$-1.41
CapEx CAGR (5Y)-10.71%
Tangible BV CAGR (5Y)64.36%
26-Week Price Return-35.32%
Quick Ratio (Annual)2.68x
13-Week Price Return-32.68%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.75x
Enterprise Value$680.485
Revenue / Share Growth (5Y)14.10%
Asset Turnover (TTM)0.36x
Book Value / Share Growth (5Y)-11.16%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-39.99%
Cash / Share (Annual)$5.37
3-Month Return Std Dev52.81%
Gross Margin (5Y Avg)57.54%
Net Income / Employee (TTM)$-0
ROE (Last FY)-28.37%
Net Interest Coverage (Annual)-4.34x
EPS Basic Excl Extra (Annual)$-1.41
Receivables Turnover (TTM)1.44x
EV / Free Cash Flow (TTM)54.63x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.41
Receivables Turnover (Annual)1.44x
ROI (TTM)-29.47%
P/S Ratio (TTM)3.56x
Pretax Margin (5Y Avg)-53.03%
Revenue / Share (Annual)$3.48
Tangible BV / Share (Annual)$7.60
Free OCF CAGR (5Y)-2.61%
Price vs S&P 500 (52W)-86.15%
Year-to-Date Return-30.98%
5-Day Price Return7.77%
EPS Normalized (Annual)$-1.41
ROA (5Y Avg)-13.36%
Net Profit Margin (Annual)-40.36%
Month-to-Date Return8.63%
Cash Flow / Share (TTM)$0.68
EBITD / Share (Annual)$-2.19
Operating Margin (Annual)-65.23%
P/CF (TTM)65.54x
ROI (5Y Avg)-23.34%
EPS Basic Excl Extra (TTM)$-1.41
P/TBV (Quarterly)4.70x
P/B Ratio (Annual)3.62x
Pretax Margin (TTM)-39.99%
Book Value / Share (Annual)$4.94
Price vs S&P 500 (13W)-35.54%
Beta1.61x
P/FCF (Annual)73.13x
Revenue / Share (TTM)$3.47
ROE (TTM)-29.47%
52-Week Low$10.95
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.06
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SDGRSchrodinger, Inc. Common Stock | 3.56x | 23.29% | 55.74% | — | $12.80 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Schrodinger is a software platform company that helps pharmaceutical, biotech, and materials science organizations accelerate molecular discovery and optimization. The company operates two segments: a Software segment that licenses its computational platform to enterprise customers (the primary revenue source), and a Drug Discovery segment that develops internal and collaborative preclinical and clinical programs. The United States represents the company's largest geographic market.